滑膜肉瘤融合基因SYT-SSX的检测及意义分析

目的研究逆转录-聚合酶链反应(RT-PCR)在滑膜肉瘤石蜡包埋组织中检测SYT-SSX融合基因的可行性和意义。方法20例滑膜肉瘤标本均用10％福尔马林固定、石蜡包埋。采用RT-PCR检测SYT-SSX融合基因。看家基因PBGD作为内参照。结果所有标本均可检测到PBGDmRNA的表达。18例(90％)检测到融合基因SYT-SSX的表达。SYT-SSX1型占12例(66．7％)，SYT-SSX2型占6例(33．3％)。结论在经福尔马林固定经石蜡包埋组织的滑膜肉瘤用RT-PCR方法检测SYT-SSX融合基因是可行的，有较高的敏感性。融合基因亚型可能为预后提供重要信息。     

滑膜肉瘤石蜡包埋组织SYT-SSX融合基因检测的临床病理意义

目的：探讨在石蜡包埋组织中检测SYT－SSX融合基因的可行性及其对滑膜肉瘤的诊断,分型和鉴别诊断的价值。方法：收集滑膜肉瘤标本38例,以恶性周围神经鞘膜瘤,纤维肉瘤,平滑肌肉瘤,尤文肉瘤,血管外皮肉瘤和转移性腺癌作为对照,共40例,均为甲醛固定,石蜡包埋组织,用逆转录－聚合酶链反应（RT－PCR）方法检测SYT－SSX融合基因mRNA表达,以看家基因PBGD作为内对照检测mRNA质量。结果：78例标本中64例（占82．1％）可检出PBGD mRNA表达,38例滑膜肉瘤中33例中可检出SYT－SSX融合基因mRNA表达,对照组无一例检出SYT－SSX基因,去除PBGD及SYT－SSX均阴性病例1例,滑膜肉瘤SYT－SSX融合基因检出率为89．2％（33／37）,33例SYT－SSX阳性滑膜肉中,SYT－SSX1型22例,SYT－SSX2型6例,5例无法区分。融合基因类型与滑膜肉瘤组织学类型有关。10例双相型滑膜肉瘤均为SYT－SSX1型,而18例单相型滑膜肉瘤中SYT－SSX1型12例,SYT－SSX2型6例,二者差异有统计学意义（P＜0．05）,结论：（1）从石蜡包埋组织中检测SYT－SSX融合基因对滑膜肉瘤有较高的敏感性和特异性,可用于滑膜肉瘤的诊断和鉴别诊断;（2）SYT－SSX融合基因类型与滑膜肉瘤组织学类型相关,SYT－SSX2型仅见于单相型。     

34例滑膜肉瘤分子遗传学改变的诊断学意义

目的 探讨石蜡包埋滑膜肉瘤组织中t(x；18)(p11．2；q11．2)染色体易位融合基因SYT-SSX mRNA表达的诊断学意义和应用价值。方法 收集滑膜肉瘤标本34例，以14例梭形细胞肉瘤和小圆细胞肉瘤做对照(包括2例纤维肉瘤、2例平滑肌肉瘤、1例恶性神经鞘膜瘤、4例Ewing肉瘤、2例腺泡型横纹肌肉瘤、2例恶性黑色素瘤、1例血管外皮瘤)。在进行免疫组织化学指标检测的基础上，用一步法逆转录-聚合酶链反应(RT-PCR)技术检测34例石蜡包埋滑膜肉瘤组织中SYT-SSX的表达。结果 34例滑膜肉瘤中30例获得有效RNA，28例(93．3％)检出SYT-SSX融合基因表达。其中14例表达SYT-SSXl型者中10例为双相型，9例表达SYT-SSX2型者中5例为单相分化型，5例SYT-SSXl／2均未检出。对照组均未检出SYT-SSX基因的表达。结论 SYT-SSX融合基因表达可作为诊断滑膜肉瘤新的分子诊断指标。一步法RT-PCR是一种理想而可行的用于石蜡包埋滑膜肉瘤组织SYT-SSX融合基因检测的分子诊断技术。     

骨软化或佝偻病相关的间叶组织肿瘤临床病理分析

目的 探讨骨软化或佝偻病相关的间叶组织肿瘤的临床病理特点。方法 回顾分析10例患者的临床资料,观察10例骨软化相关的肿瘤组织的形态和免疫表型[免疫组织化学SP法染色,所用抗体包括波形蛋白、S-100、平滑肌肌动蛋白（SMA）、结蛋白、CD34、AE1／AE3、Ki-67、HMB45]。结果 患者男性6例,女性4例,年龄范围28～69岁（平均45．6岁）;患者均有2～27年（平均9．6年）骨痛、关节痛和活动困难的病史,检查发现低血磷、高尿磷;肿瘤最大径1～7cm不等（平均3．5cm）;瘤组织为间叶组织来源（仅2例颌骨病变中见不明显的条索状上皮）,可见多少不等的梭形纤维母细胞样细胞、脂肪细胞、软骨样细胞、黏液样细胞等,瘤组织富于血管,8例病变中有少见的絮状或不规则砂砾样钙盐沉积,2例发生于软组织的肿瘤周边见骨壳形成。3例组织中可见非尿酸盐结晶：9例细胞分裂象少见,1例核分裂象多见并且异型性明显;瘤细胞波形蛋白阳性,5例SMA部分阳性,3例CD34部分瘤细胞阳性,结蛋白、S-100、AE1／AE3均阴性,Ki-67指数（8例≤4％,仅1例为30％）;AB／PAS染色：8例肿瘤黏液基质和血管周围黏液样变呈AB染色阳性。结论 骨软化相关的肿瘤多为良性或低度恶性的间叶组织肿瘤,因组织学具有多样性而易误诊,掌握其共性特征并结合临床资料方能正确诊断。     

Renal small cell oncocytoma with pseudorosettes A histomorphologic, immunohistochemical, and molecular genetic study of 10 cases

A cohort of a heretofore not described rare subtype of renal oncocytoma, small cell oncocytoma with pseudorosettes is presented. Patients were 6 women and 4 men with ages ranging from 51 to 76 years. The tumors displayed areas composed of small cells ("oncoblasts") featuring scant cytoplasm and small, round monomorphic nuclei. The small cell areas constituted 15% to 60% of the total tumor volume (mean, 28.5%; median, 22.5%). No necrosis or mitotic activity was discerned. All tumors also contained areas composed of characteristic oncocytes comprising 40% to 85% of the total tumor volume. In all cases, a varying number of pseudorosettes were identified. The pseudorosettes were composed of small globules of (periodic acid-Schiff-positive) hyaline basal membrane-like material surrounded by small "oncoblastic" cells. The immunohistochemical profile was variable, including at least focal positivity for AE1-3 (10/10), cytokeratin 7 (7/10), epithelial membrane antigen (10/10), c-kit (6/10), antimitochondrial antigen (MIA;10/10), PAX-2 (9/10), AMACR (racemase;6/10), CD10 (5/10), parvalbumin (8/10), vimentin (6/10), claudin 7 (10/10), and claudin 8 (3/10). No immunoreactivity for carbonic anhydrase 9, HMB-45, S-100A1, and TFE3 was documented. We found no differences in the immunophenotype in the small cell oncocytes/oncoblasts that formed pseudorosettes and those that did not. However, there were differences in the immunohistochemical profile of classic oncocytes and small cell oncocytes/oncoblasts. Using array comparative genomic hybridization, no chromosomal changes were identified in any of the cases examined (n = 3). No numerical changes of chromosomes 7 and 17 were revealed on fluorescence in situ hybridization analysis (n = 3). In conclusion, we herein present the first study on small cell renal oncocytomas with formation of pseudorosettes. This is a rare subtype of oncocytoma, which may, especially on a core biopsy, present differential diagnostic difficulties. The immunohistochemical profile of these tumors is variable and differs in significant respects from that of conventional renal oncocytoma. Awareness of this entity and its immunohistochemical variability should help in distinguishing this rare tumor from malignant tumors with similar (small cell) histomorphologic features. All tumors behaved in a benign fashion during follow-up (mean, 3.1 years; median, 1 year).     

原发性肾脏滑膜肉瘤临床病理及分子遗传学分析

目的探讨原发性肾脏滑膜肉瘤的临床病理特征、诊断及鉴别诊断。方法对1例罕见的原发性肾脏滑膜肉瘤进行光镜观察和免疫组化染色,并用RT-PCR方法在石蜡包埋组织中检测SYT-SSX融合mRNA表达,结合文献分析讨论。结果肿瘤由核分裂活跃的单形的梭形细胞组成,呈交织的束状或实性排列,部分区域呈血管外皮瘤样图像,未见上皮分化成分;囊性区囊内衬核分裂不活跃的多边形的鞋钉样上皮。免疫表型瘤细胞vimentin、CD99、bcl-2、S-100均阳性,Ki-67强阳性;CK(AE1/AE3)、EMA、SMA、CD117、CD34、p53、ER、PR均阴性。RT-PCR方法检测到肿瘤组织中有SYT-SSXmRNA表达,对照组SYT-SSX无表达。患者术后5月内死亡。结论原发性肾脏滑膜肉瘤罕见,需要与肾脏其他一些梭形细胞肿瘤相鉴别,分子遗传学检测SYT-SSX融合mRNA有助于其诊断和鉴别诊断。     

滑膜肉瘤的融合基因检测分析

目的：基于存在染色体易位所致特异的SYT－SSX融合基因,证实可在滑膜肉瘤组织石蜡切片上检测出并探讨其在诊断中的价值。方法：采用逆转录－聚合酶链反应,检测并分析20例滑膜肉瘤（组织学亚型15例单相,5例双相）的SYT－SSX转录物,并对照相应病理学所见,结果：所检20例滑膜肉瘤中,有19例（95％）出现特异SYT－SSX逆转录聚酶链反应产物,其中13例具有SYT－SSX2融合基因的肿瘤有10例呈组织学单相分化。结论：SYT－SSX融合基因转录物可在石蜡切片和组织块中获得满意结果。具有较好的灵敏性,是滑膜肉瘤所特有的诊断标志物,它的亚类分型（SYT－SSX1和SYT－SSX2）,可能成为预后推测指征。     

Uterine tumors resembling ovarian sex cord tumors,a clinicopathologic study of six cases

Uterine tumors resembling ovarian sex cord tumors (UTROSCTs) cause difficulties, both with respect to diagnosis as well as to the nomenclature. They belong to the group of low-grade malignant neoplasms, and their clinical course likely depends on the percentage of the sex cord–like component. Morphologically, they can be divided into type I and type II with less or more than 50% of sex cord–like areas, respectively. Six patients with an age range of 24 to 63 years underwent the treatment for primary UTROSCT at the Cancer Center and Institute of Oncology in Warsaw, Poland, between 2000 and 2011. In addition to the surgery, 4 patients were treated with gestagens. Biopsies or excisions from the tumors were examined microscopically and immunohistochemically. Two cases were classified as type I, and 4 cases, as type II tumors. The tumor size ranged from 3 to 24 cm. The sex cord component varied from 25% to 70%. By immunohistochemical examination, the sex cord–like component was calretinin positive, whereas the stromal component was positive for CD10 and negative for h-caldesmon in all the cases studied. In addition, progesterone receptor positivity was found in all the cases, and 4 tumors were positive for smooth muscle actin, cytokeratin AE1/3, and inhibin. No recurrences were noted in any of the 6 patients over 3 to 14.5 years of follow-up period. A correct subclassification of sarcomas of UTROSCT type is of crucial importance because most patients with this rare neoplasm respond well to gestagen therapy and have a good prognosis, compared with other uterine stromal sarcomas.